Patient support hubs have quietly become one of the most strategically important — and most contested — functions in pharmaceutical commercialization. For years, the model was simple: manufacturers launched a specialty drug, handed enrollment, reimbursement, and adherence support to a third-party hub vendor, and moved on. That playbook is now being rewritten. A wave of 2026...